A Novel Therapeutic Approach Targeting Coronavirus Replication-Essential RNAs by Oligonucleotides
Project ID : 47-2020-10912
The research team plans to develop a drug to inhibit human SARS-CoV-2 replication. They will use comparative genomics to detect conserved regions within the coronavirus family, and within human CoV-19 population, in order to identify essential genes that can be targeted to inhibit the virus replication.
The drug will be a relevant allele-specific oligonucleotide (ASOs), to be delivered into the lung epithelial cells. Following delivery into lung cells, the ASOs will bind the virus’ essential mRNAs, activate RNAse and induce degradation of these mRNAs, and inhibit replication of the virus in the cells.
Project manager
Mel Larrosa
VP Business Development Healthcare
Project researchers
Rotem Karni
HUJI, School of Medicine - IMRIC
Biochemistry and Molecular Biology
Yuval Tabach
HUJI, School of Medicine - IMRIC
Developmental Biology and Cancer Research
Alexander Rouvinski
HUJI, School of Medicine - IMRIC
Microbiology and Molecular Genetics